- Home
- STCN vs ENTX Comparison
STCN vs ENTX Comparison
Compare STCN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- ENTX
- Stock Information
- Founded
- STCN 1986
- ENTX 2010
- Country
- STCN United States
- ENTX Israel
- Employees
- STCN N/A
- ENTX N/A
- Industry
- STCN Advertising
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STCN Consumer Discretionary
- ENTX Health Care
- Exchange
- STCN Nasdaq
- ENTX Nasdaq
- Market Cap
- STCN 63.4M
- ENTX 67.2M
- IPO Year
- STCN 1994
- ENTX 2018
- Fundamental
- Price
- STCN $9.80
- ENTX $1.75
- Analyst Decision
- STCN
- ENTX Strong Buy
- Analyst Count
- STCN 0
- ENTX 1
- Target Price
- STCN N/A
- ENTX $10.00
- AVG Volume (30 Days)
- STCN 30.8K
- ENTX 128.1K
- Earning Date
- STCN 12-12-2024
- ENTX 11-08-2024
- Dividend Yield
- STCN N/A
- ENTX N/A
- EPS Growth
- STCN 203.29
- ENTX N/A
- EPS
- STCN 3.11
- ENTX N/A
- Revenue
- STCN $174,109,000.00
- ENTX $99,000.00
- Revenue This Year
- STCN N/A
- ENTX N/A
- Revenue Next Year
- STCN N/A
- ENTX N/A
- P/E Ratio
- STCN $3.27
- ENTX N/A
- Revenue Growth
- STCN N/A
- ENTX 607.14
- 52 Week Low
- STCN $7.36
- ENTX $0.52
- 52 Week High
- STCN $13.00
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- STCN 40.83
- ENTX 45.87
- Support Level
- STCN $9.66
- ENTX $1.64
- Resistance Level
- STCN $10.32
- ENTX $1.84
- Average True Range (ATR)
- STCN 0.61
- ENTX 0.10
- MACD
- STCN -0.02
- ENTX -0.01
- Stochastic Oscillator
- STCN 8.81
- ENTX 35.48
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.